Ranolazine

雷诺嗪

Report date: 2026/03/12 20:00:16
NMEFirst In Class

Base Information

Drug NameRanolazine
Drug Alias NameRanolazinum雷诺拉嗪雷诺嗓ranolazinaRanexa +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type V alpha subunit blockers
TargetsSodium channel protein type V alpha subunit
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Myocardial Infarction +[26] 
Global Approved IndicationsAngina Pectoris
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/01/27
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesFederico Ii UniversityMenarini International Operations Luxembourg SaThe University Of Kansas Medical Center +[7] 
Inactive CompaniesCv TherapeuticsThe Brigham and Women's HospitalAspirus Heart And Vascular Institute-Research And Education +[17] 
Active IndicationsMyocardial InfarctionAngina, StableAngina Pectoris +[4] 
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Coronary Artery Disease +[22] 

Other Information

ATC CodeC01EB18
Related LinksWikipediaDrugBankKEGG